---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-26-000019"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T07:59:56.020221+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Autolus enters 10-year lentiviral vector supply deal with AGC Biologics

## Summary
- Master Service Agreement with AGC Biologics for lentiviral vector, critical for CAR-T production.
- Minimum purchase: 14 batches in first 2 years; EUR 25 million over subsequent 5 years.
- AGC granted first right to negotiate manufacturing of obe-cel (obecabtagene autoleucel).
- 10-year fixed term, non-exclusive; Autolus can terminate with certain fees, either party for default.
- Agreement replaces prior arrangement; individual work orders govern specific projects.

## SEC filing metadata
- accession: 0001730463-26-000019
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/0001730463-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/autl-20260121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-26-000019
- JSON: https://secwatch.observer/filing/0001730463-26-000019.json
- Plain text: https://secwatch.observer/filing/0001730463-26-000019.txt

## Key facts
- Material Agreements
  Autolus Therapeutics plc entered into Master Service Agreement with AGC Biologics S.p.A. valued at EUR 25 million (effective 2026-01-21).
  - Action: entry
  - Agreement: supply
  - Counterparty: AGC Biologics S.p.A.
  - Value: EUR 25 million
  - Effective: 2026-01-21
  source text: On January 21, 2026, Autolus Limited, a wholly owned subsidiary of Autolus Therapeutics plc (the “ registrant ”, and together with Autolus Limited, the “ Company ”), entered into a Master Service Agreement with AGC Biologics S.p.A (“ AGC ”) for the manufacture and supply of lentiviral vector (the “ Agreement ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000019/0001730463-26-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.